9-Me-BC

A beta-carboline sold on claims of being a "dopamine regenerator" — cell studies showed increased dopamine neuron growth and tyrosine-hydroxylase expression, which the nootropic market translated into cognitive-enhancement capsules.

9-Me-BC (9-methyl-beta-carboline) is a beta-carboline alkaloid reported in rodent work to increase dopamine neuron activity and to show neuroprotective and neurorestorative effects in models of dopaminergic damage. The proposed mechanism combines mild monoamine oxidase inhibition with effects on dopamine synthesis and on neurotrophic signalling. The interest comes from the neurorestorative claim specifically — the animal work suggested it did not just raise dopamine but supported the neurons themselves, which is a more ambitious claim than most compounds in this section make.

Cell culture and rodent data only, from a small research literature. No human trials of any kind. The mechanistic story is genuinely interesting neuroscience and genuinely untested medicine.

• NONE. There is no human trial of 9-Me-BC of any size or phase.
• The entire evidence base is rodent and cell-culture work from a small number of research groups.
• The beta-carboline class is a genuine reason for caution rather than a neutral structural fact: some beta-carbolines are neurotoxic, and the class includes compounds implicated in neurological damage. Structural relatives are not a safety argument here.
• Monoamine oxidase inhibition, even mild, carries real interaction consequences with serotonergic drugs and with tyramine-containing foods — and that is a class property that would be expected to apply.
• Sold as research-chemical supply of unverified identity, concentration and purity.

Human pharmacokinetics have never been characterised — no bioavailability, half-life or clearance figure exists for people. Any such number in circulation is animal extrapolation. Reported MAO inhibition is the pharmacological property with the clearest potential for harm through interaction.

9-Me-BC itself inhibited MAO-A and MAO-B in vitro — so interactions with common drugs and supplements (stimulants, SSRIs, tyramine) are pharmacologically plausible, with human clinical relevance unknown. The beta-carboline family also includes known neurotoxins, which raises the stakes of "no human data." Photosensitivity is a theoretical concern from the compound class's light-reactive chemistry, not an established human effect.

• Anyone taking serotonergic medication, given the serotonin syndrome risk from MAO-inhibiting activity
• Anyone with uncontrolled hypertension
• Anyone with Parkinson's disease self-treating with it in place of managed care
• Anyone pregnant or breastfeeding
• Anyone unwilling to accept an uncharacterised research chemical from a class containing neurotoxic members

• SSRIs, SNRIs, tricyclics, triptans, tramadol and other serotonergic drugs — serotonin syndrome risk with any MAO-inhibiting compound.
• Tyramine-containing foods including aged cheese, cured meats and fermented products, which is the classic MAO-inhibitor dietary interaction.
• Other MAO inhibitors, stimulants, and anything raising blood pressure.
• No characterised human profile exists — these are class-based expectations rather than measured findings.

• There is no established monitoring for a compound with zero human data.
• The interaction risk is the concrete one: anyone taking serotonergic medication needs to understand that a compound with MAO-inhibiting activity is a serotonin syndrome risk, and this one has never been characterised.
• Any severe headache, chest pain or blood-pressure symptom after eating aged or fermented foods, which is the classic MAO-inhibitor concern.

Nothing is established about stopping because nothing is established about taking it. No withdrawal syndrome is described and no demonstrated effect exists to lose.

US: unscheduled, unapproved research chemical.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's disease
  Pharmacol Rep, 2010
• The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects
  J Neurochem, 2010
• 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture
  Neurochem Int, 2008

• Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug?Expert Rev Neurother · 2011
• 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytesJ Neural Transm (Vienna) · 2020
• Correction to: 9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytesJ Neural Transm (Vienna) · 2022
• 9-Methyl-beta-carboline has restorative effects in an animal model of Parkinson's diseasePharmacol Rep · 2010
• Mechanisms of DNA damage by photoexcited 9-methyl-β-carbolinesOrg Biomol Chem · 2013
• 9-Methyl-β-carboline-induced cognitive enhancement is associated with elevated hippocampal dopamine levels and dendritic and synaptic proliferationJ Neurochem · 2012
• 9-Methyl-beta-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic cultureNeurochem Int · 2008
• Photophysical and Photochemical Properties of Naturally Occurring normelinonine F and Melinonine F Alkaloids and Structurally Related N(2)- and/or N(9)-methyl-β-carboline DerivativesPhotochem Photobiol · 2018
• The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effectsJ Neurochem · 2010
• Good guys from a shady familyJ Neurochem · 2012
• New agents promote neuroprotection in Parkinson's disease modelsCNS Neurol Disord Drug Targets · 2012
• Inhibition of the bioactivation of the neurotoxin MPTP by antioxidants, redox agents and monoamine oxidase inhibitorsFood Chem Toxicol · 2011